Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$772M |
| 2 |
Eli Lilly
LLY
|
+$337M |
| 3 |
lululemon athletica
LULU
|
+$301M |
| 4 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$297M |
| 5 |
ResMed
RMD
|
+$273M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$576M |
| 2 |
AT&T
T
|
+$476M |
| 3 |
PNC Financial Services
PNC
|
+$393M |
| 4 |
Fortive
FTV
|
+$389M |
| 5 |
Accenture
ACN
|
+$374M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 2.83% |
| 2 | Technology | 2.79% |
| 3 | Financials | 2.29% |
| 4 | Consumer Discretionary | 1.93% |
| 5 | Industrials | 1.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
9351
CALL
Cullinan Oncology
CGEM
$1.31B
| $351K | ﹤0.01% |
27,400
-101,900
| -79% | -$1.16M |
|
9352
GATX Corp
GATX
$6.38B
| $351K | ﹤0.01% |
+3,734
| New | +$398K |
|
9353
Invitation Homes
INVH
$18B
| $351K | ﹤0.01% |
9,876
-540,526
| -98% | -$20.6M |
|
9354
NewMarket
NEU
$8.85B
| $351K | ﹤0.01% |
1,165
-7,929
| -87% | -$2.56M |
|
|
OPI
9355
CALL
DELISTED
Office Properties Income Trust
OPI
| $351K | ﹤0.01% |
17,600
+3,000
| +21% | +$64.9K |
|
9356
Pacer Swan SOS Moderate October ETF
PSMO
$101M
| $351K | ﹤0.01% |
+17,898
| New | +$362K |
|
9357
PUT
ACI Worldwide
ACIW
$5.4B
| $350K | ﹤0.01% |
13,500
-18,400
| -58% | -$495K |
|
9358
PUT
ACM Research
ACMR
$5.6B
| $350K | ﹤0.01% |
20,800
-138,200
| -87% | -$2.13M |
|
9359
CALL
Fortis
FTS
$29B
| $350K | ﹤0.01% |
7,400
+3,100
| +72% | +$152K |
|
|
FUNL
9360
DELISTED
CornerCap Fundametrics Large-Cap ETF
FUNL
| $350K | ﹤0.01% |
+11,295
| New | +$377K |
|
9361
Preformed Line Products
PLPC
$2.27B
| $350K | ﹤0.01% |
+5,691
| New | +$352K |
|
9362
Invesco FTSE RAFI US 1000 ETF
PRF
$10.1B
| $350K | ﹤0.01% |
11,820
-12,940
| -52% | -$416K |
|
9363
Pacer Swan SOS Flex October ETF
PSFO
$39M
| $350K | ﹤0.01% |
+17,856
| New | +$362K |
|
9364
CALL
Supernus Pharmaceuticals
SUPN
$2.81B
| $350K | ﹤0.01% |
12,100
-2,500
| -17% | -$71.6K |
|
9365
CALL
Cactus
WHD
$5.88B
| $350K | ﹤0.01% |
8,700
+1,200
| +16% | +$60.3K |
|
|
EIGR
9366
CALL
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $350K | ﹤0.01% |
1,853
-214
| -10% | -$43.1K |
|
9367
CALL
Smartbird Inc
BIRD
$30.1M
| $349K | ﹤0.01% |
4,440
-11,060
| -71% | -$1.12M |
|
9368
CALL
Carpenter Technology
CRS
$27B
| $349K | ﹤0.01% |
12,500
-26,000
| -68% | -$925K |
|
9369
Glaukos
GKOS
$10.9B
| $349K | ﹤0.01% |
7,684
-47,361
| -86% | -$2.25M |
|
9370
CALL
Home BancShares
HOMB
$6.28B
| $349K | ﹤0.01% |
16,800
+5,100
| +44% | +$110K |
|
9371
Pacer Data & Infrastructure Real Estate ETF
SRVR
$391M
| $349K | ﹤0.01% |
10,121
-40,441
| -80% | -$1.48M |
|
9372
CALL
Xeris Biopharma Holdings
XERS
$1.57B
| $349K | ﹤0.01% |
226,300
+21,000
| +10% | +$44.3K |
|
|
VIA
9373
DELISTED
Via Renewables, Inc. Class A Common Stock
VIA
| $349K | ﹤0.01% |
+9,105
| New | +$358K |
|
|
WE
9374
PUT
DELISTED
WeWork Inc.
WE
| $349K | ﹤0.01% |
1,740
-2,568
| -60% | -$661K |
|
|
IS
9375
CALL
DELISTED
ironSource Ltd.
IS
| $349K | ﹤0.01% |
146,800
+22,300
| +18% | +$74.7K |
|
Similar funds
Ken Griffin's Q2 2022 Portfolio in Review
As of Q2 2022, Ken Griffin held 14,957 positions worth $390B, down 20% from $484B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Ken Griffin's Q2 2022 filing shows 1,520 new, 5,503 increased, 5,522 reduced and 2,191 closed positions. Its largest new stake was ResMed: 1,280,595 shares worth $268M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $576M.
By sector, the portfolio is most concentrated in Healthcare at 2.8% of assets, up from 2.4% a quarter earlier, followed by Technology and Financials.
- Ken Griffin's largest Q2 2022 buy was ResMed: 1,280,595 shares worth $268M.
- Ken Griffin added most to Meta Platforms (Facebook) in Q2 2022, an estimated $772M increase.
- Ken Griffin's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $576M.
- Ken Griffin fully exited Vanguard Morningstar Small-Cap ETF in Q2 2022, selling an estimated $184M.
- Ken Griffin's ten largest holdings make up 28% of its $390B portfolio in Q2 2022.
- Ken Griffin opened 1,520 new positions and closed 2,191 in Q2 2022.
- Ken Griffin's portfolio value fell 20% quarter-over-quarter to $390B.
Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.